Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Completed · Phase 3

Conditions studied: HIV-1 Infection

In brief

The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.

Key facts

Study ID

NCT03631732

Run by

Gilead Sciences

People needed

496

Starts

2018-08-28

Expected to finish

2020-08-19

Last updated by the study team

2021-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alabama Medical Group, PC — Mobile, Alabama, United States
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
• Ruane Clinical Research Group Inc. — Los Angeles, California, United States
• Mills Clinical Research — Los Angeles, California, United States
• Highland Hospital- Alameda Health System — Oakland, California, United States
• Kaiser Permanente — Oakland, California, United States
• One Community Health — Sacramento, California, United States
• Kaiser Permanente — Sacramento, California, United States
• Kaiser Permanente, Department of Infectious Diseases — San Leandro, California, United States
• Whitman-Walker Health — Washington D.C., District of Columbia, United States
• Georgetown University Hospital — Washington D.C., District of Columbia, United States
• Dupont Circle Physician's Group — Washington D.C., District of Columbia, United States
• Washington Health Institute — Washington D.C., District of Columbia, United States
• Capital Medical Associates, PC — Washington D.C., District of Columbia, United States
• The GW Medical Faculty Associates — Washington D.C., District of Columbia, United States
• Midland Florida Clinical Research Center, LLC — DeLand, Florida, United States
• Therafirst Medical Center — Fort Lauderdale, Florida, United States
• Gary J. Richmond, M.D., P.A. — Fort Lauderdale, Florida, United States
• Midway Immunology and Research Center — Ft. Pierce, Florida, United States
• AHF- The Kinder Medical Group — Miami, Florida, United States
• University of Miami School of Medicine Division of Infectious Disease — Miami, Florida, United States
• AIDS Healthcare Foundation - South Beach — Miami Beach, Florida, United States
• Orlando Immunology Center — Orlando, Florida, United States
• St. Joseph's Hospital Comprehensive Research Institute — Tampa, Florida, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.